#28 Catching black swans – François Montastruc

Serious and unexpected adverse drug reactions – the ‘black swans’
of pharmacovigilance – can place enormous strain on safety
monitoring systems. Drawing examples from the COVID-19 pandemic,
François Montastruc from Toulouse University Hospital explains
how we can get better at dealing with the unpredictable.


Tune in to find out:


What Nassim Nicholas Taleb’s ‘black swan’ theory has to do
with pharmacovigilance

What makes an adverse drug reaction a black, white, or grey
swan

 Why flexibility and communication are key to patient
safety



Want to know more?
Here are the research articles cited in the episode:


Quality of reporting of adverse events in clinical trials of
COVID-19 drugs: systematic review

Psychiatric disorders and hydroxychloroquine for COVID-19: a
VigiBase study

Hepatic disorders with the use of remdesivir for COVID-19

Serious bradycardia and remdesivir for COVID-19: a new safety
concern

Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous
thrombosis and thrombocytopaenia: a missed opportunity for a
rapid return of experience

Atypical thrombosis associated with VaxZevria (AstraZeneca)
vaccine: data from the French network of regional
pharmacovigilance centres

Teaching pharmacovigilance to French medical students during
the COVID-19 pandemic: interest of distance learning clinical
reasoning sessions



If you enjoyed this podcast, check out these related episodes
from the Drug Safety Matters archive:


Reforming pharmacovigilance education

Lessons in pandemic pharmacovigilance

Intuition in pharmacovigilance






Join the conversation on social mediaFollow us on
Facebook, LinkedIn, X, or Bluesky and share your thoughts about
the show with the hashtag #DrugSafetyMatters.

Got a story to share?We’re always looking for new
content and interesting people to interview. If you have a great
idea for a show, get in touch!

About UMCRead more about Uppsala Monitoring Centre
and how we work to advance medicines safety.